A Phase 2a, Dose Escalation Study to Evaluate the Effect of RT234 on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

16 Oct 2020 According to a Respira Therapeutics media release, data from the study will be presented at the American College of Chest Physicians virtual CHEST Annual Meeting 2020. Highlights of the clinical presentation and full data presented at the CHEST Annual Meeting 2020 are available on the Respira website.
16 Oct 2020 Results presented in a Respira Therapeutics media release.
22 Apr 2020 Status changed from recruiting to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com